New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2013
06:04 EDTSSNLF, PFE, AAPL, MSFT, GSKOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: With the realization that Microsoft’s (MSFT) new Windows 8 software will not reignite computer sales, attention is shifting to the company's next big effort to regain relevance: Windows Blue, the software project which has yet to formally defined, the Wall Street Journal reports...Of the hundreds of millions of dollars paid each year to compensate physicians for pharmaceutical marketing and research efforts, Pfizer (PFE) and GlaxoSmithKline (GSK) are cutting back. In addition, layoffs of pharmaceutical-sales representatives and patent expirations for big-selling drugs have resulted in fewer sales calls on doctors, the Wall Street Journal reports...REUTERS: World shares declined today as investors locked in profits at the end of what was set to be the second best week of the year for stocks, while the dollar held near a four-year high against the yen, Reuters reports...No fewer than three Wall Street analysts this week wrote reports about the possibility of the biggest banks breaking themselves up to increase profitability, signaling that investors may be more willing to embrace an idea that is still toxic to some lawmakers in Washington, Reuters reports..BLOOMBERG: Apple (AAPL) and Samsung (SSNLF) are being beaten on price in the fast-growing Indian smartphone market by a couple of aggressive local competitors, fueled by Indians buying their first smartphone to surf the Internet, which will be accessed by more than 300M people by 2017, Bloomberg reports...Gold swung between gains and declines as it headed for a third weekly drop in London on speculation a strengthening U.S. economy will curb demand for a protection of wealth. Prices are down 7% this year on rising optimism that the U.S. will help lead a global economic recovery, Bloomberg reports.
News For MSFT;PFE;GSK;AAPL;SSNLF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 >>
August 24, 2015
06:18 EDTAAPLApple announces repair program for blurry iPhone 6 Plus cameras
Subscribe for More Information
05:45 EDTAAPLStocks with implied volatility movement; AAPL EFA
Subscribe for More Information
August 23, 2015
19:03 EDTAAPLApple hires Tesla engineer for 'special projects' division
Subscribe for More Information
14:23 EDTAAPLApple, Micron shares look like bargains, Barron's says
Subscribe for More Information
12:35 EDTPFEBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
16:01 EDTAAPLOptions Update; August 21, 2015
Subscribe for More Information
13:50 EDTAAPLOn The Fly: Weekly technical notes, Gold, S&P 500, Germany, China, Energy
Subscribe for More Information
12:49 EDTAAPLReport: Apple may be working on smart bands for Watch, Apple Insider says
Apple may be working on "smart bands" for the Apple Watch product in order to add more health tracking functions, reports Apple Insider, citing Czech website Letem Svetem Applem. Citing unnamed sources, the Czech website said Apple is planning to announce new bands that will connect the hidden port of the Apple Watch and add functionality to the device. The smart bands could launch as early as 2016. Reference Link
12:43 EDTAAPLJim Chanos says still long Apple, short HP
Subscribe for More Information
12:18 EDTMSFTMicrosoft to cut up to 2,300 jobs in Finland, Reuters reports
Microsoft (MSFT) will cut up to 2,300 jobs in Finland and close Nokia's (NOK) former handset product development unit in Salo, Reuters reports. The cuts are part of Microsoft's plans to cut 7,800 jobs globally. Microsoft will keep open sites in Espoo and Tampere. Reference Link
10:37 EDTMSFTAnalysts upbeat on HP ahead of split after earnings beat
Subscribe for More Information
10:34 EDTSSNLFSamsung working on Android tablet with 18.4-inch display, Sam Mobile reports
Subscribe for More Information
10:23 EDTAAPLApple falls, levels to watch
Subscribe for More Information
09:34 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL FB BAC NFLX DIS TSLA TWTR
08:11 EDTAAPLDaimler AG could collaborate with Google, Apple, Reuters says
Subscribe for More Information
08:01 EDTPFEPfizer says two Phase 3 Trumenba studies met primary endpoints
Subscribe for More Information
06:01 EDTAAPL, MSFT, SSNLFABI Research: Portable PC sales to remain flat in 2015, DigiTimes says
Subscribe for More Information
06:01 EDTSSNLFReport: Samsung TV production capacity reduced in 1H15, DigiTimes says
Samsung reduced TV production capacity globally by 10M units in 1H15, reports DigiTimes. Citing Korea media reports in Money Today, Samsung reduced capacity to 21.36M in 1H15. It also plans to decrease production capacity by another 10M units in 2H15 for a total of 42M units. Reference Link
06:01 EDTMSFTInterDigital sued by Microsoft for violating antitrust law, Reuters reports
Microsoft (MSFT) has filed a lawsuit against InterDigital (IDCC), accusing the company of violating U.S. antitrust law by unfairly licensing its technology, Reuters reports. The suit, filed in federal court in Wilmington, Delaware, is the latest move in the companies' fight over patent licensing. The ITC is set to rule this month on whether Microsoft's smartphones infringe two of InterDigital patents and should be banned from being imported into the U.S. Reference Link
05:25 EDTGSKNovartis acquires all remaining rights to Ofatumumab from GSK
Novartis (NVS) announced that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis, or RRMS, and other autoimmune indications. Novartis previously acquired the rights to Ofatumumab for oncology indications and it is marketed under the brand name Arzerra. Novartis will be responsible for the worldwide development, regulatory and commercialization activities for Ofatumumab. Under the terms of the agreement, Novartis will make an initial upfront payment of $300M to GSK for the acquisition of the compound and a further payment of $200M payable following the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, contingent payments of up to $534M may be made. Novartis will also pay royalties of up to 12% to GSK on any future net sales of Ofatumumab in autoimmune conditions.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use